BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29476608)

  • 1. Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
    Biswas A; Leon ME; Drew P; Fernandez-Bussy S; Furtado LV; Jantz MA; Mehta HJ
    Diagn Cytopathol; 2018 May; 46(5):378-383. PubMed ID: 29476608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
    Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
    Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer.
    Smith A; Wang H; Zerbo A; Beaudoin S; Ofiara L; Fiset PO; Benedetti A; Gonzalez AV
    J Bronchology Interv Pulmonol; 2020 Jan; 27(1):50-57. PubMed ID: 31513030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields.
    Khoury LM; Sheehan KN; Mariencheck WI; Gershner KA; Maslonka M; Niehaus AG; Isom S; Bellinger CR
    Lung; 2024 Jun; 202(3):325-330. PubMed ID: 38637361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration samples for programmed death ligand-1 testing in non-small cell lung cancer, the Bristol experience.
    Hardy J; Bhatt N; Medford ARL
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e32-e38. PubMed ID: 33870634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.
    Perrotta F; Nankivell M; Adizie JB; Maqsood U; Elshafi M; Jafri S; Lerner AD; Woolhouse I; Munavvar M; Evison M; Booton R; Baldwin DR; Janes SM; Kerr KM; Bianco A; Yarmus L; Navani N
    Chest; 2020 Sep; 158(3):1230-1239. PubMed ID: 32428509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
    Yoshimura K; Inoue Y; Karayama M; Tsuchiya K; Mori K; Suzuki Y; Iwashita Y; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Yokomura K; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2019 Aug; 134():202-209. PubMed ID: 31319982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration to assess tumor-programmed cell death ligand-1 expression in mediastinal lymph nodes metastasized from non-small cell lung cancer.
    Mineura K; Hamaji M; Yoshizawa A; Nakajima N; Kayawake H; Tanaka S; Yamada Y; Yutaka Y; Nakajima D; Ohsumi A; Menju T; Chen-Yoshikawa TF; Date H
    Surg Today; 2020 Sep; 50(9):1049-1055. PubMed ID: 32166496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.
    Koomen BM; Vreuls W; de Boer M; de Ruiter EJ; Hoelters J; Vink A; Willems SM
    Histopathology; 2021 Oct; 79(4):480-490. PubMed ID: 33772818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.
    Stoy SP; Rosen L; Mueller J; Murgu S
    Cancer Cytopathol; 2018 Feb; 126(2):122-128. PubMed ID: 29053224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration With Stylet Retracted Partially Versus Completely for Molecular Testing.
    Fernandez-Bussy S; Biswas A; Labarca G; Jantz MA; Mehta HJ
    J Bronchology Interv Pulmonol; 2019 Jul; 26(3):222-224. PubMed ID: 31107296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Hara N; Ichihara E; Harada D; Inoue K; Fujiwara K; Hosokawa S; Kishino D; Haruyuki K; Ochi N; Oda N; Hotta K; Maeda Y; Kiura K
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3749-3755. PubMed ID: 33779840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of endobronchial ultrasound transbronchial needle aspiration as the first nodal staging procedure for the determination of programmed death ligand-1 expression in non-small cell lung cancer patients.
    Polanco D; Pinilla L; Gracia-Lavedan E; Gatius S; Zuil M; Pardina M; Gómez S; Barbé F
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12459-12468. PubMed ID: 37450028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
    Sakakibara R; Inamura K; Tambo Y; Ninomiya H; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Matsuura Y; Nakao M; Mun M; Okumura S; Inase N; Nishio M; Motoi N; Ishikawa Y
    Clin Lung Cancer; 2017 Sep; 18(5):527-534.e1. PubMed ID: 28111119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study.
    Murthy V; Katzman DP; Tsay JJ; Bessich JL; Michaud GC; Rafeq S; Minehart J; Mangalick K; de Lafaille MAC; Goparaju C; Pass H; Sterman DH
    Lung Cancer; 2019 Nov; 137():94-99. PubMed ID: 31563736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
    BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.